A Phase 2 interventional study of GLK-221 Ophthalmic Solution and Placebo Ophthalmic Solution in Keratoconus, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
This study's planned enrollment of 100 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Browse Keratoconus studies →Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLK-221 Ophthalmic Solution administered topically twice daily to both eyes
Drug: GLK-221 Ophthalmic Solution
Placebo Ophthalmic Solution administered topically twice daily to both eyes
Drug: Placebo Ophthalmic Solution
GLK-221 Ophthalmic Solution administered twice daily to both eyes
Placebo Ophthalmic Solution administered twice daily to both eyes
Mean change from baseline in maximum corneal curvature
Mean change from baseline in maximum corneal curvature
Time frame: 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.